Merck beats estimates on fourth-quarter on earnings

Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Merck Shares Hit After Guidance Falls Short, Gardasil Challenge
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
FiercePharma18h
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Wells Fargo Remains a Hold on Merck & Company (MRK)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report), with a ...
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Merck Posts Quarterly Profit on Sales Growth
The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.
STAT11h
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...